Drugs / Pandemic flu H5 mRNA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06727058 | Dec 2024 → Mar 2026 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pandemic flu H5 mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06727058 ↗ |
| Modality | Messenger RNA (mRNA) | “pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine” NCT06727058 ↗ |
| Route | Intramuscular | “Route of Administration: Intramuscular (IM)” NCT06727058 ↗ |